Intrathecal Double Checkpoint Inhibition

NCT05598853 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Leptomeningeal Metastasis
Non-small Cell Lung Cancer Stage IV
Melanoma Stage IV

Interventions

DRUG: intrathecal nivolumab and intrathecal ipilimumab

Sponsor

University of Zurich